couter

Cigna Corporation (CI) is a health insurance and managed care provider with a broad footprint in the U.S. health care system, offering employer-sponsored and individual health plans, pharmacy benefits, and specialty services. The next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to sustain growth in its pharmacy and specialty drug businesses amid rising medical costs and regulatory pressures.

  • Revenue reached $277.09B in 2026, up 11.2% YoY, with net income of $6.17B and free cash flow of $3.55B.
  • Margins remain tight at 2.2% net margin, but leverage is moderate at 0.95x debt-to-equity.
  • Shareholders’ equity stands at $41.71B, with a diluted EPS of $6.29.
Jan 20, 2027 — PBM Legislative & Executive Scrutiny Under President Trump
Chart by TradingView

The schedule

  • Wed20Jan

    The event will test how Cigna navigates potential regulatory changes and legislative actions impacting its PBM operations, which could affect its revenue and profitability.

  • Thu4Feb

    This release will test Cigna's ability to sustain growth in its PBM and specialty pharmacy lines, particularly amid regulatory scrutiny and pricing pressures, which differs from the last print where the focus was on short-term revenue.

  • Tue30Mar

    The event will test Cigna's ability to validate the growth potential of its specialty pharmacy and GLP-1 segments, which could impact its long-term revenue and market position.

  • Thu6May

    The release will test Cigna's ability to maintain its growth trajectory in the face of macroeconomic headwinds and regulatory headwinds, particularly in its specialty pharmacy and GLP-1 segments, which differ from the last print where the focus was on short-term revenue.

  • Thu5Aug

    This release will test Cigna's ability to sustain its growth in a more mature market, particularly in its PBM and specialty pharmacy lines, which differ from the last print where the focus was on short-term revenue.

  • Thu30Sep

    The event will test Cigna's ability to communicate its long-term strategy and growth prospects to investors, which could impact its stock price and market perception.

  • Thu4Nov

Past

  • Thu5Nov

    Actual outcome: Bear

    Cigna reported an EPS actual of 25.24, matching the estimate, but the stock fell 2.6% as investors focused on weaker-than-expected guidance for specialty pharmacy and PBM segments, which failed to meet expectations for top-line growth and margin expansion. The lack of clarity on long-term growth prospects and margin pressure overshadowed the earnings beat, pushing the stock below the bear floor.

    The earnings release will test whether Cigna can deliver strong top-line growth and margin expansion, particularly in its specialty pharmacy and PBM segments, which differ from the last print where guidance was overly optimistic.

  • Thu7May

    Actual outcome: Bull · $299.16 at outcome

    Cigna delivered strong Q1 results, beating adjusted EPS estimates ($7.79 vs $7.62) and reporting a 5% increase in total revenues driven by 9% growth in its Evernorth unit. The company also raised its full-year 2026 adjusted EPS outlook to at least $30.35 and announced plans to exit the ACA individual exchange market to focus on core businesses, reinforcing the bullish fundamental case despite a muted initial price reaction.

  • Sun15Mar

    Actual outcome: Mixed · $270.36 at outcome

    The stock remained flat following the CMS announcement as the final 2027 Medicare Advantage payment rates likely met baseline expectations without providing a positive surprise to offset broader sector headwinds. While Cigna's Evernorth segment continues to drive strong revenue growth and management has a history of earnings beats, persistent concerns regarding rising medical costs and conservative 2026 guidance kept the price centered between the bull and bear targets.

  • Thu5Feb

    Actual outcome: Bull · $287.61 at outcome

    The outcome was bullish as Cigna reported a Q4 2025 adjusted EPS beat ($8.08 vs. $7.88 estimate) and strong full-year revenue growth, alongside a "modestly higher 2026 earnings outlook." Management commentary addressed key concerns regarding medical cost trends and highlighted continued strength in the Evernorth segment, validating the company's low P/E valuation thesis. This strong fundamental performance drove the stock past the $288 bull target.

Scouting Reports